Jain Pritesh P, Hosokawa Susumu, Xiong Mingmei, Babicheva Aleksandra, Zhao Tengteng, Rodriguez Marisela, Rahimi Shamin, Pourhashemi Kiana, Balistrieri Francesca, Lai Ning, Malhotra Atul, Shyy John Y-J, Valdez-Jasso Daniela, Thistlethwaite Patricia A, Makino Ayako, Yuan Jason X-J
Section of Physiology, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, CA, USA.
Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan.
Pulm Circ. 2020 Nov 25;10(4):2045894020956592. doi: 10.1177/2045894020956592. eCollection 2020 Oct-Dec.
Hypoxic Pulmonary Vasoconstriction (HPV) is an important physiological mechanism of the lungs that matches perfusion to ventilation thus maximizing O saturation of the venous blood within the lungs. This study emphasizes on principal pathways in the initiation and modulation of hypoxic pulmonary vasoconstriction with a primary focus on the role of Ca signaling and Ca influx pathways in hypoxic pulmonary vasoconstriction. We used an ex vivo model, isolated perfused/ventilated mouse lung to evaluate hypoxic pulmonary vasoconstriction. Alveolar hypoxia (utilizing a mini ventilator) rapidly and reversibly increased pulmonary arterial pressure due to hypoxic pulmonary vasoconstriction in the isolated perfused/ventilated lung. By applying specific inhibitors for different membrane receptors and ion channels through intrapulmonary perfusion solution in isolated lung, we were able to define the targeted receptors and channels that regulate hypoxic pulmonary vasoconstriction. We show that extracellular Ca or Ca influx through various Ca-permeable channels in the plasma membrane is required for hypoxic pulmonary vasoconstriction. Removal of extracellular Ca abolished hypoxic pulmonary vasoconstriction, while blockade of L-type voltage-dependent Ca channels (with nifedipine), non-selective cation channels (with 30 µM SKF-96365), and TRPC6/TRPV1 channels (with 1 µM SAR-7334 and 30 µM capsazepine, respectively) significantly and reversibly inhibited hypoxic pulmonary vasoconstriction. Furthermore, blockers of Ca-sensing receptors (by 30 µM NPS2143, an allosteric Ca-sensing receptors inhibitor) and Notch (by 30 µM DAPT, a γ-secretase inhibitor) also attenuated hypoxic pulmonary vasoconstriction. These data indicate that Ca influx in pulmonary arterial smooth muscle cells through voltage-dependent, receptor-operated, and store-operated Ca entry pathways all contribute to initiation of hypoxic pulmonary vasoconstriction. The extracellular Ca-mediated activation of Ca-sensing receptors and the cell-cell interaction via Notch ligands and receptors contribute to the regulation of hypoxic pulmonary vasoconstriction.
缺氧性肺血管收缩(HPV)是肺部一种重要的生理机制,它使灌注与通气相匹配,从而使肺内静脉血的氧饱和度最大化。本研究着重于缺氧性肺血管收缩起始和调节的主要途径,主要关注钙信号传导和钙内流途径在缺氧性肺血管收缩中的作用。我们使用离体模型,即分离灌注/通气的小鼠肺来评估缺氧性肺血管收缩。在分离灌注/通气的肺中,肺泡缺氧(利用小型呼吸机)由于缺氧性肺血管收缩而迅速且可逆地增加肺动脉压。通过在离体肺中经肺灌注溶液应用针对不同膜受体和离子通道的特异性抑制剂,我们能够确定调节缺氧性肺血管收缩的靶向受体和通道。我们发现,缺氧性肺血管收缩需要细胞外钙或通过质膜中各种钙通透通道的钙内流。去除细胞外钙可消除缺氧性肺血管收缩,而阻断L型电压依赖性钙通道(用硝苯地平)、非选择性阳离子通道(用30 μM SKF - 96365)以及TRPC6/TRPV1通道(分别用1 μM SAR - 7334和30 μM辣椒素)可显著且可逆地抑制缺氧性肺血管收缩。此外,钙敏感受体阻滞剂(用30 μM NPS2143,一种变构钙敏感受体抑制剂)和Notch阻滞剂(用30 μM DAPT,一种γ-分泌酶抑制剂)也减弱了缺氧性肺血管收缩。这些数据表明,肺动脉平滑肌细胞中通过电压依赖性、受体操纵性和储存操纵性钙内流途径的钙内流均有助于缺氧性肺血管收缩的起始。细胞外钙介导的钙敏感受体激活以及通过Notch配体和受体的细胞间相互作用有助于缺氧性肺血管收缩的调节。